SeaMatics is an "advanced materials manufacturing project for photonic integrated circuits" for a range of emerging applications in optical communication, sensors, imaging technology for healthcare, and lighting. Unlike the integration in electronic circuits in which electrons flow seamlessly, in photonic integrated circuits at the light does not flow seamlessly due to mismatch of refractive index and materials dissimilarity. In order to facilitate a way forward for fabricating light circuits, the SeaMatics team has embarked on research which will exploit a novel "ultrafast laser plasma implantation (ULPI)" based technique for fabricating complex structures, using following materials: rare-earth ion doped glass, polymers and silicon and GaAs semiconductors. Such a combinatorial approach for materials fabrication will yield photonic circuit for engineering range energy-efficient devices for cross-sectorial applications (health, manufacturing, energy, digital). The project is led by the University of Leeds and is supported by has four academic partners by the Universities of Cambridge, Sheffield and York in the respective areas of research on polymeric devices, III-V semiconductors, and silicon photonics. The EPSRC National Centre for III-V Technologies will be accessed for materials and device fabrication. Eleven industry partners directly involved in the project are: DSTL, GTS/British Glass, Glucosense/NetScientific, Product Evolution, PVD Products, CST, IQE, Dow Corning, Xyratex, Gooch and Housego and Semtech. The industry links covers from materials manufacturing to optical components and their applications in optical/data communication, sensors for healthcare, energy for lighting. In this partnership the manufacturing is linked with different levels of supply chain, which we aim to demonstrate by researching on exemplar devices as end points. The main goals of the project are a) Set up a ULPI manufacturing capability at Leeds which will serve the needs of academic and industrial communities in UK to start with and then expand for international collaboration. b) Our first application led manufacturing example will demonstrate ULPI based RE-earth doped glass photonic circuits with light splitting, lasing and amplification functions on a chip. c) In another example we will demonstrate electrically pumped semiconductor lasers (VCSEL and VECSEL) and integrated with rare-earth ion doped glass for broadband and tunable lasers. d) Approaches developed in b) and c) will be then expanded for manufacturing larger scale photonic integrated circuits on silicon, embodying multiple functions using the techniques developed in a). e) ULPI as technique will be applied for engineering novel range of polymer-glass sensor devices which will be used for health care. f) The final goal of project is to provide training, dissemination, and outreach opportunities for new researchers in SeaMatics. Dissemination related activities will be via the standard peer-review publications in prestigious journals, conferences and workshops. Dedicated symposia are planned for dissemination, and also the outreach activities involving UG/PG interns, PhD students and Sixth form pupils.

Photonics is one of six EU "Key Enabling Technologies. The US recently announced a $200M programme for Integrated Photonics Manufacturing to improve its competiveness. As a UK response, the research proposed here will advance the pervasive technologies for future manufacturing identified in the UK Foresight report on the Future of Manufacturing, improving the manufacturability of optical sensors, functional materials, and energy-efficient growth in the transmission, manipulation and storage of data. Integration is the key to low-cost components and systems. The Hub will address the grand challenge of optimising multiple cross-disciplinary photonic platform technologies to enable integration through developing low-cost fabrication processes. This dominant theme unites the requirements of the UK photonics (and photonics enabled) industry, as confirmed by our consultation with over 40 companies, Catapults, and existing CIMs. Uniquely, following strong UK investment in photonics, we include most of the core photonic platforms available today in our Hub proposal that exploits clean room facilities valued at £200M. Research will focus on both emerging technologies having greatest potential impact on industry, and long-standing challenges in existing photonics technology where current manufacturing processes have hindered industrial uptake. Platforms will include: Metamaterials: One of the challenges in metamaterials is to develop processes for low-cost and high-throughput manufacturing. Advanced metamaterials produced in laboratories depend on slow, expensive production processes such as electron beam writing and are difficult to produce in large sizes or quantities. To secure industrial take up across a wide variety of practical applications, manufacturing methods that allow nanostructure patterning across large areas are required. Southampton hosts a leading metamaterials group led by Prof Zheludev and is well positioned to leverage current/future EPSRC research investments, as well as its leading intellectual property position in metamaterials. High-performance special optical fibres: Although fibres in the UV and mid-IR spectral range have been made, few are currently commercial owing to issues with reliability, performance, integration and manufacturability. This platform will address the manufacturing scalability of special fibres for UV, mid-IR and for ultrahigh power sources, as requested by current industrial partners. Integration with III-V sources and packaging issues will also be addressed, as requested by companies exploiting special fibres in laser-based applications. In the more conventional near-infrared wavelength regime, we will focus on designs and processes to make lasers and systems cheaper, more efficient and more reliable. Integrated Silicon Photonics: has made major advances in the functionality that has been demonstrated at the chip level. Arguably, it is the only platform that potentially offers full integration of all the key components required for optical circuit functionality at low cost, which is no doubt why the manufacturing giant, Intel, has invested so much. The key challenge remains to integrate silicon with optical fibre devices, III-V light sources and the key components of wafer-level manufacture such as on line test and measurement. The Hub includes the leading UK group in silicon photonics led by Prof Graham Reed. III-V devices: Significant advances have been made in extending the range of III-V light sources to the mid-IR wavelength region, but key to maximise their impact is to enable their integration with optical fibres and other photonics platforms, by simultaneous optimisation of the III-V and surrounding technologies. A preliminary mapping of industrial needs has shown that integration with metamaterial components optimised for mid-IR would be highly desirable. Sheffield hosts the EPSRC III-V Centre and adds a powerful light emitting dimension to the Hub.

The unique properties of light have made it central to our high-tech society. For example, our information-rich world is only enabled by the remarkable capacity of the fibre-optic network, where thin strands of glass are used to carry massive amounts of information around the globe as high-speed optical signals. Light also impacts areas of our society as diverse as laser-based manufacturing, solar energy, space-based remote sensing and even astronomy. One area where the properties of light open up otherwise-impossible capabilities is medicine. In ophthalmology for example, lasers are routinely used to perform surgery on the eye through corneal reshaping. This involves two different lasers. In the first step, a laser producing very short pulses of infrared light cuts a flap in the front surface of the eye to provide access. In the second step, another laser producing longer pulses of ultraviolet (UV) light sculpts the shape of the cornea and correct focusing errors. The flap is then folded back into place so that the cornea can heal. The two very-different laser systems in that example illustrate an important point: the effects of light on human tissues are highly-dependent on the specific properties of both the light and the tissues involved. To sculpt the cornea, the laser wavelength of 193 nm is in the deep UV region of the electromagnetic spectrum, much shorter than the visible range (380 - 740 nm) we are familiar with. This is because (unlike visible light) it is very efficiently absorbed by the cornea, so that essentially all the energy of the light is deposited at the surface. Thus only a very thin layer of tissue (a few microns thick) is removed, or "resected", with each pulse of light, facilitating very-precise shaping of the cornea and accurate adjustment of its focusing properties. 193 nm light can be generated by an ArF excimer gas laser, a >40 year-old technology producing a poor-quality low-brightness beam of light. This is suitable for corneal reshaping, but not for a range of other important therapies requiring higher-quality deep UV beams. Unfortunately, alternative ways to generate such short wavelengths are non-trivial, resulting in complex and expensive laser systems not suitable for widespread clinical uptake. U-care aims to address this gap by exploiting cutting-edge techniques in laser physics. We will develop new sources of deep UV light which will be highly compact, robust and low cost. We will develop ways to deliver this light precisely to tissues, and work to understand in detail the biophysical mechanisms involved. Our efforts will focus on new therapies that target some of the biggest challenges facing medicine: cellular-precision cancer surgery, and the emergence of drug-resistant "super-bugs". Importantly, U-care will involve engineers and physical scientists working in close collaboration with clinicians and biomedical scientists to verify that the therapies we develop are effective and safe. By doing so in an integrated manner, we will drive our deep-UV light therapies towards healthcare impact and widespread use in the clinic by 2050.

Glass has been a key material for many important advances in civilization; it was glass lenses which allowed microscopes to see bacteria for the first time and telescopes which revealed the planets and the moons of Jupiter. Glassware itself has contributed to the development of chemical, biological and cultural progress for thousands of years. The transformation of society with glass continues in modern times; as strands of glass optical fibres transform the internet and how we communicate. Today, glasses have moved beyond transparent materials, and through ongoing research have become active advanced and functional materials. Unlike conventional glasses made from silica or sand, research is now producing glasses from materials such as sulphur, which yields an unusual, yellow orange glass with incredibly varied properties. This next generation of speciality glasses are noted for their functionality and their ability to respond to optical, electrical and thermal stimuli. These glasses have the ability to switch, bend, self-organize and darken when exposed to light, they can even conduct electricity. They transmit light in the infra-red, which ordinary glass blocks and the properties of these glasses can even change, when strong light is incident upon them. The demand for speciality glass is growing and these advanced materials are of national importance for the UK. Our businesses that produce and process materials have a turnover of around £170 billion per annum; represent 15% of the country's GDP and have exports valued at £50 billion. With our proposed research programme we will produce extremely pure, highly functional glasses, unique to the world. The aims of our proposed research are as follows: - To establish the UK as a world-leading speciality glass research and manufacturing facility - To discovery new and optimize existing glass compositions, particularly in glasses made with sulphur - To develop links with UK industry and help them to exploit these new glass materials - To demonstrate important new electronic, telecommunication, switching devices from these glasses - To partner other UK Universities to explore new and emerging applications of speciality glass To achieve these goals we bring together a world-class, UK team of physicists, chemists, engineers and computer scientists from Southampton, Exeter, Oxford, Cambridge and Heriot-Watt Universities. We are partners with over 15 UK companies who will use these materials in their products or contribute to new ways of manufacturing them. This proposal therefore provides a unique opportunity to underpin a substantial national programme in speciality-glass manufacture, research and development.

The EPSRC Centre in Innovative Manufacturing in Medical Devices will research and develop advanced methods for functionally stratified design and near patient manufacturing, to enable cost effective matching of device function to the patient needs and surgical environment. This will deliver "the right product, by the right process to the right patient at the right time" to an enhanced standard of reliability and performance. The centre will research and develop: 1) Functionally stratified design systems, which will be initially applied to existing device manufacturing processes and subsequently to the manufacture of scaffolds, developing novel pre-clinical simulation methods, which match implant design to patient function, delivering a cost effective Stratified Approach for Enhanced Reliability (SAFER) 2) Innovative near patient manufacturing processes, enabled by stratified and individualised definitions of patient need, to provide a more cost effective approach to personalised devices. The two flagship challenges will be integrated with the key platform capabilities, across the centre to generate, for the first time, a closed loop design and manufacturing framework for medical devices to deliver enhanced performance and reliability. These innovative design and manufacturing advances will focus in the first instance on class 3 medical devices for musculoskeletal disease, where the cost of device failure and need for throughout life reliability are high. The National Centre will develop, lead and integrate an international network of industrialists, academics, clinicians and regulatory body representatives in order to support the musculoskeletal medical device manufacturing industry to deliver the innovative design and manufacturing challenges and implement the outcomes into manufacturing practice in a global highly regulated market. The Centre will create the research infrastructure, tools and methods, expertise and suitably qualified personnel to support continued innovation and growth of the medical device manufacturing sector in the UK. To do so, the Centre will work across the EPSRC priority research areas "Manufacturing the Future" and "Towards next generation healthcare," drawing upon capabilities and collaborating with existing centres of excellence. The Centre will provide a platform for fundamental innovative device manufacturing research and promote its rapid exploitation by industry through outreach and translation activities and a generic platform for diversification into other technologies. It will grow the UK's research capability in medical device manufacturing research to underpin the development of next generation medical devices and the development of high quality manufacturing processes to provide cost effective, reliable and effective devices. It will be applied to enhanced manufacturing of existing devices such as joint replacements and support manufacture of new products and biomaterial scaffolds. The Centre will operate across five leading academic centres of excellence in the field. The Centre will be led by Leeds University (Fisher, Williams, Ingham, Wilcox, Jennings and Redmond) and will be supported by collaboration from Newcastle (Dalgarno and McKaskie), Nottingham (Grant, Ahmed and Warrior), Sheffield (Hatton) and Bradford (Coates). The Centre will work closely with major manufacturers and users including surgeons who see at first hand the challenges of patient and surgical variation. The Centre will provide a platform for developing fundamental medical device manufacturing science and promote its rapid exploitation by industry.